New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Eikon Therapeutics, Inc. (EIKN) vs Scribe Therapeutics Inc. (SCTX)

Eikon Therapeutics, Inc. and Scribe Therapeutics Inc. are both Biotechnology companies. Eikon Therapeutics, Inc. and Scribe Therapeutics Inc. are of similar size ($257.9M and $250.4M). Across the 3 metrics below, Eikon Therapeutics, Inc. leads on 2 and Scribe Therapeutics Inc. on 1.

Valuation

Metric EIKN SCTX Biotechnology median
P/E n/m n/m 8.49
P/S — 6.75 8.56
P/B 0.67 1.40 2.04
Price to free cash flow n/m — 23.84
EV/EBITDA 0.61 n/m 0.69
EV/Sales — 0.02 8.00
Earnings yield (670.53%) (80.87%) (35.81%)
Free cash flow yield (103.42%) — (25.41%)

Profitability

Metric EIKN SCTX Biotechnology median
Gross margin — — 70.18%
Operating margin — — 0.00%
Net margin — — 0.00%
Free cash flow margin — — 0.00%
Return on equity 359.35% — (51.58%)
Return on assets (56.31%) — (45.91%)
Return on invested capital 0.00% — 0.00%

Growth

Metric EIKN SCTX Biotechnology median
Revenue growth (TTM) — — 7.20%
EPS growth (last fiscal year) (19.15%) — 29.04%
Revenue growth, 5-year CAGR — — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric EIKN SCTX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.21 4.72 4.79
Net debt to EBITDA 1.07 — 1.01

Dividend

Metric EIKN SCTX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric EIKN SCTX Biotechnology median
Market cap 257.93m 250.35m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack